Coppell Advisory Solutions LLC Buys 2,846 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Coppell Advisory Solutions LLC raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 74.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,686 shares of the pharmaceutical company’s stock after acquiring an additional 2,846 shares during the quarter. Coppell Advisory Solutions LLC’s holdings in Vertex Pharmaceuticals were worth $2,951,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. United Services Automobile Association bought a new position in Vertex Pharmaceuticals in the first quarter valued at $2,933,000. Lee Johnson Capital Management LLC purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth about $721,000. Police & Firemen s Retirement System of New Jersey increased its position in shares of Vertex Pharmaceuticals by 3.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company’s stock valued at $17,378,000 after purchasing an additional 1,393 shares during the last quarter. Bailard Inc. lifted its position in Vertex Pharmaceuticals by 0.5% in the 2nd quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company’s stock worth $16,983,000 after buying an additional 200 shares during the last quarter. Finally, SteelPeak Wealth LLC purchased a new stake in Vertex Pharmaceuticals in the second quarter worth approximately $10,059,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 63,781 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total transaction of $28,650,425.20. Following the transaction, the chairman directly owned 24,026 shares of the company’s stock, valued at approximately $10,792,479.20. The trade was a 72.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Charles F. Wagner, Jr. sold 14,000 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the completion of the sale, the executive vice president directly owned 37,725 shares of the company’s stock, valued at approximately $17,202,600. This represents a 27.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 151,073 shares of company stock worth $67,326,816 over the last three months. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 1.4%

VRTX stock opened at $452.04 on Friday. The stock has a market capitalization of $114.69 billion, a price-to-earnings ratio of 31.88 and a beta of 0.32. The firm’s 50-day moving average price is $426.51 and its two-hundred day moving average price is $425.61. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.58 by $0.22. The company had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Vertex Pharmaceuticals had a return on equity of 23.51% and a net margin of 31.35%.Vertex Pharmaceuticals’s quarterly revenue was up 11.0% on a year-over-year basis. During the same period last year, the firm earned $4.38 earnings per share. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on VRTX shares. Stifel Nicolaus decreased their price target on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating on the stock in a research note on Tuesday, November 4th. Scotiabank assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $495.00 target price on the stock. Citigroup boosted their price target on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. Barclays raised their price objective on Vertex Pharmaceuticals from $408.00 to $414.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 4th. Finally, Wells Fargo & Company boosted their target price on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an “overweight” rating in a research note on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $498.42.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.